Pierre Fabre Medical

Company snapshot

The Pierre Fabre Group, founded by a pharmacist Pierre Fabre, is the second largest private pharmaceutical company in France. Owned by a government recognised public interest foundation, the Group is committed to designing and developing innovative solutions to contribute to the wellbeing of everyone through products across consumer health, dermo-cosmetics and pharmaceuticals. In Australia, Pierre

• 4 approved product(s) across US/EU regulatory metadata.
• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Pierre Fabre Medical. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Pierre Fabre Medical.

1. Jun 8, 2026 Clinical update

   The impact of extra-fine inhalation corticost... — Approved

2. Jun 8, 2026 Clinical update

   The papillon study — Approved

3. Jun 8, 2026 Clinical update

   LIDOCAINE HYDROCHLORIDE, MORPHINE HYDROCHLORIDE — Approved

View all clinical trial activity →

• What is Pierre Fabre Medical?

  Pierre Fabre Australia is a pharma organization headquartered in AU. Primary therapeutic focus areas include sickle cell anaemia, Chronic Obstructive Pulmonary Disease. NovaPharmaNews links 3 clinical program(s), 2 drug profile(s), and 0 patent record(s) to this entity from publi

• Is Pierre Fabre Medical publicly traded?

  Pierre Fabre Medical appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Pierre Fabre Medical develop or market?

  We link 18 drug profile(s) where Pierre Fabre Medical is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pierre-fabre-m-dicament#company-drugs.

• What are the latest developments for Pierre Fabre Medical?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Pierre Fabre Medical focus on?

  Pierre Fabre Medical focuses on sickle cell anaemia, Chronic Obstructive Pulmonary Disease based on our analysis of their pipeline programs and drug development activities.